Hostname: page-component-cd9895bd7-jkksz Total loading time: 0 Render date: 2024-12-31T14:40:36.788Z Has data issue: false hasContentIssue false
  • English
  • Français

The Causality of Depression in Schizophrenia

Published online by Cambridge University Press:  29 January 2018

Joe Galdi  and
Steven R. Hirsch
Joe Galdi
Affiliation:
Behavioral Neurology Program, New Hampshire Hospital, Concord, New Hampshire 03301, USA
Steven R. Hirsch
Affiliation:
Department of Psychiatry, Charing Cross Hospital Medical School, London W6
Get access Rights & Permissions [Opens in a new window]

Extract

The phenomenon of post-treatment depression in schizophrenia has become the subject of considerable controversy regarding its causality (Ananth and Chadirian, 1980; McGlashan and Carpenter, 1976a). But as the recent commentary by Hirsch (1982) emphasizes, the most controversial issue is focused on whether this depression is neuroleptic-induced. Hirsch himself refutes neuroleptic-induction on the basis of various uncontrolled data which seem ostensibly incompatible with this causality. Results indicating that pretreatment depressions appear in a high proportion of recently hospitalized schizophrenics, occur in drug-free patients, and frequently remit or decrease following neuroleptic therapy are cited as evidence contradicting neuroleptic-induction. Hirsch therefore proposes an alternative view: that this post-treatment depression is an integral, “revealed” aspect of the schizophrenia syndrome which arises from the same pathophysiological process (cf. McGlashan and Carpenter, 1976b).

Type
Discussion
Information
The British Journal of Psychiatry , Volume 142 , Issue 6 , June 1983 , pp. 621 - 625
Copyright
Copyright © 1983 The Royal College of Psychiatrists 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Ananth, J. & Chadirian, A. M. (1980) Drug induced mood disorder. International Pharmacopsychiatry, 15, 58–73.CrossRefGoogle Scholar
Casey, J. F., Bennett, I. F., Lindsey, C. J. et al (1960) Drug therapy of schizophrenia: a controlled study of the relative effectiveness of chlorpromazine, promazine, phenobarbital, and placebo. Archives of General Psychiatry, 117, 997–1003.Google Scholar
Floru, L., Heinrich, K. & Witter, F. (1975) The problem of postpsychotic schizophrenic depression and their pharmacological induction. International Pharmacopsychiatry, 10, 230–9.Google Scholar
Galdi, J., Rieder, R. O., Silber, D. & Bonato, R. R. (1981) Genetic factors in the response to neuroleptics in schizophrenia: a psychopharmacogenetic study. Psychological Medicine, 11, 713–28.CrossRefGoogle ScholarPubMed
Herz, M. I. & Melville, C. (1980) Relapse in schizophrenia. American Journal of Psychiatry, 137, 801–5.Google Scholar
Hirsch, S. R. (1982) Depression “revealed” in schizophrenia. British Journal of Psychiatry, 140, 421–4.Google Scholar
Hogarty, G. E., Schooler, N. R., Ulrich, R. et al (1979) Fluphenazine and social therapy in the aftercare of schizophrenic patients. Archives of General Psychiatry, 36, 1283–94.Google Scholar
Johnson, D. A. W. (1981) Studies of depressive symptoms in schizophrenia. British Journal of Psychiatry, 139, 89–101.CrossRefGoogle ScholarPubMed
Knights, A. & Hirsch, S. R. (1981) “Revealed” depression and drug treatment for schizophrenia. Archives of General Psychiatry, 38, 806–11.Google Scholar
Mandel, M. R., Severe, J. B., Schooler, N. R. et al (1982) Development and prediction of postpsychotic depression in neuroleptic-treated schizophrenics. Archives of General Psychiatry, 39, 197–203.CrossRefGoogle ScholarPubMed
McGlashan, T. H. & Carpenter, W. T. (1976a) Postpsychotic depression in schizophrenia. Archives of General Psychiatry, 33, 231–9.Google Scholar
McGlashan, T. H. & Carpenter, W. T. (1976b) An investigation of the postpsychotic depressive syndrome. American Journal of Psychiatry, 133, 14–19.Google Scholar
Moller, H. J. & von Zerssen, D. (1982) Depressive states occurring during the neuroleptic treatment of schizophrenia. Schizophrenia Bulletin, 8, 109–17.Google Scholar
Snyder, S., Greenberg, D. & Yamamura, H. I. (1974) Antischizophrenic drugs and brain cholinergic receptors. Archives of General Psychiatry, 31, 58–61.Google Scholar
van Kammen, D. P., Alexander, P. E. & Bunney, W. E. (1980) Lithium treatment in postpsychotic depression. British Journal of Psychiatry, 136, 479–85.Google Scholar
Casey, J. F., Bennett, I. F., Lindley, C. J. et al (1960) Drug therapy of schizophrenia: a controlled study of the relative effectiveness of chlorpromazine, promazine, phenobarbitol and placebo. Archives of General Psychiatry, 117, 997–1003.Google Scholar
Galdi, J., Reider, R. O., Silber, D. & Bonato, R. R. (1981) Genetic factors in the response to neuroleptics in schizophrenia: a psychopharmacogenetic study. Psychological Medicine, 11, 713–28.Google Scholar
Hirsch, S. R. (1982) Depression “revealed” in schizophrenia. British Journal of Psychiatry, 140, 421–4.Google Scholar
Johnson, D. A. W. (1981) Studies of depressive symptoms in schizophrenia. British Journal of Psychiatry, 139, 89–101.CrossRefGoogle ScholarPubMed
Knights, A. & Hirsch, S. R. (1981) Revealed depression and drug treatment for schizophrenia. Archives of General Psychiatry, 38, 806–11.CrossRefGoogle ScholarPubMed
Moller, H. J. & von Zerssen, D. (1981) Depressive Symptomatik in Stationären Behandlungsverlauf von 280 schizophrenen Patienten. Pharmakopsychiatrie, 14, 172–9.Google Scholar
Moller, H. J. & von Zerssen, D. (1982) Depressive states occuring during the neuroleptic treatment of schizophrenia. Schizophrenia Bulletin, 8, 109–17.Google Scholar
Wing, J. K., Cooper, J. E. & Sartorius, N. (1974) The Measurement and Classification of Psychiatric Symptoms. London: Cambridge University Press.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.